ARVN Arvinas (ARVN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001655759
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
113
13F, latest reported quarter
What the filings say about ARVN
Insiders, 180 days
-$518.2K net sold
5 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$867.6K
4 notices
Arvinas insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ARVINAS, INC. insiders sold a net $518.2K of stock across 152 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 11, 2026.
- The trade is 3.0% of the 187,432 shares held after it.
- 1 other insider sold within 30 days.
- 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Saik Andrew sold about $46.5K of ARVN on Jun 24, 2026; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on May 11, 2026.
- The trade is 1.4% of the 180,390 shares held after it.
- 2 other insiders sold within 30 days.
- 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Cacace Angela M sold about $19.6K of ARVN on Jun 17, 2026; 2 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on May 11, 2026.
- The trade is 0.8% of the 285,009 shares held after it.
- 4 other insiders sold within 30 days.
- 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Teel Randy sold about $20.0K of ARVN on May 21, 2026; 4 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 13, 2026.
- The trade is 5.8% of the 193,128 shares held after it.
- 4 other insiders sold within 30 days.
- 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Saik Andrew sold about $110.7K of ARVN on May 11, 2026; 4 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 23, 2026.
- The trade is 4.8% of the 40,193 shares held after it.
- 4 other insiders sold within 30 days.
- 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, Chief Accounting Officer Loomis David K sold about $19.1K of ARVN on May 11, 2026; 4 other insiders sold within 30 days and 113 funds added in the latest 13F quarter.152 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$518.2K over 180 days
below 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
113 funds bought in last quarter
more than 73% of Pharma & Biotech
Revenue
-0.3% year over year
below 57% of Pharma & Biotech
Margin
-30.8% net margin
more than 55% of Pharma & Biotech
Buybacks
$91.9M repurchased, FY to 2025-12-31
more than 67% of Pharma & Biotech
Short interest
9.8% of the float short (float per yahoo 2026-10-27) · 8.2 days to cover · settled 2026-10-15
more than 67% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 8 in the prior 90
Why it matters
The absence is the signal: 8 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch ARVN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-18.7%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ARVN: institutional holders (13F)
13F holdings, latest reported quarter
7,609,123 sh
$63.2M
4,123,399 sh
$34.3M
3,495,153 sh
$29.0M
3,457,815 sh
$27.7M
2,796,000 sh
$23.2M
Congress trades in ARVN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ARVN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
SUNIL AGARWAL
Filed 2026-09-22
$196.2K
NOAH C BERKOWITZ
Filed 2026-09-09
$328.9K
NOAH C BERKOWITZ
Filed 2026-09-04
$78.4K
NOAH C BERKOWITZ
Filed 2026-08-04
$264.0K
NOAH C BERKOWITZ
Filed 2026-07-09
$201.5K
ARVN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$5.3M position · as of 2026-06-30
1.2%
PROFUND VP PHARMACEUTICALS
$139.3K position · as of 2026-06-30
1.2%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$185.5K position · as of 2026-07-31
0.9%
Virtus Biotech Clinical Trials Etf
$329.3K position · as of 2026-07-31
0.7%
AlphaCentric Life Sciences and Healthcare Fund
$254.5K position · as of 2026-06-30
0.5%
Tema Oncology ETF
$755.4K position · as of 2026-05-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Phase 2
0 active
3
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · John Houston, Ph.D.
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.5M
$2.6M
$2.8M
-86%
+25%
2024
$12.7M
$3.2M
$3.4M
-77%
-7%
2023
$7.6M
$6.0M
$2.7M
-52%
-6%
2022
$9.5M
$6.7M
$3.5M
-60%
-10%
2021
$12.6M
$9.3M
$4.3M
-3%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $518.2K sold by insiders over 180 days, 113 funds added last quarter, $867.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ARVN financials
Revenue growth
-0.3%
XBRL, annual
Net margin
-30.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$316.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ARVN
| FY Dec 2025 | $262.6M |
| FY Dec 2024 | $263.4M |
| FY Dec 2023 | $78.5M |
| FY Dec 2022 | $131.3M |
| FY Dec 2021 | $53.6M |
| Jun 2026 | $249.7M |
| Mar 2026 | $15.6M |
| Dec 2025 | $9.5M |
| Sep 2025 | $41.9M |
| Jun 2025 | $22.4M |
| Mar 2025 | $188.8M |
| Dec 2024 | $59.2M |
| Sep 2024 | $102.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+2.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ARVN
| FY Dec 2025 | -30.8% |
| FY Dec 2024 | -75.6% |
| FY Dec 2023 | -467.5% |
| FY Dec 2022 | -215.5% |
| FY Dec 2021 | -356.6% |
| Jun 2026 | +67.8% |
| Mar 2026 | -369.2% |
| Dec 2025 | -711.6% |
| Sep 2025 | -83.8% |
| Jun 2025 | -273.2% |
| Mar 2025 | +43.9% |
| Dec 2024 | -76.4% |
| Sep 2024 | -48.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$208.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ARVN
| FY Dec 2025 | -$275.7M |
| FY Dec 2024 | -$261.1M |
| FY Dec 2023 | -$350.7M |
| FY Dec 2022 | -$280.3M |
| FY Dec 2021 | $554.7M |
| Jun 2026 | -$48.5M |
| Mar 2026 | -$70.5M |
| Dec 2025 | -$30.6M |
| Sep 2025 | -$59.2M |
| Jun 2025 | -$96.6M |
| Mar 2025 | -$89.3M |
| Dec 2024 | -$84.4M |
| Sep 2024 | -$128.7M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ARVN
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-414.00x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ARVN
| FY Dec 2025 | -456.33x |
| FY Dec 2024 | -324.12x |
| FY Dec 2023 | -347.80x |
| FY Dec 2022 | -273.50x |
| FY Dec 2021 | 522.07x |
| Jun 2026 | -414.00x |
| Mar 2026 | -508.20x |
| Dec 2025 | -456.33x |
| Sep 2025 | -545.83x |
| Jun 2025 | -566.29x |
| Mar 2025 | -358.14x |
| Dec 2024 | -324.12x |
| Sep 2024 | -322.88x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+1.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ARVN
| FY Dec 2025 | -16.3% |
| FY Dec 2024 | -32.6% |
| FY Dec 2023 | -59.9% |
| FY Dec 2022 | -42.0% |
| FY Dec 2021 | -26.8% |
| Jun 2026 | +1.6% |
| Mar 2026 | -42.3% |
| Dec 2025 | -16.3% |
| Sep 2025 | -10.2% |
| Jun 2025 | -12.0% |
| Mar 2025 | -7.4% |
| Dec 2024 | -32.6% |
| Sep 2024 | -59.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ARVN
| FY Dec 2025 | -9.0% |
| FY Dec 2024 | -16.6% |
| FY Dec 2023 | -28.5% |
| FY Dec 2022 | -19.9% |
| FY Dec 2021 | -16.6% |
| Jun 2026 | +1.1% |
| Mar 2026 | -26.9% |
| Dec 2025 | -9.0% |
| Sep 2025 | -5.8% |
| Jun 2025 | -6.6% |
| Mar 2025 | -4.2% |
| Dec 2024 | -16.6% |
| Sep 2024 | -27.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital ARVN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-2.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ARVN
| FY Dec 2025 | -16.5% |
| FY Dec 2024 | -26.2% |
| FY Dec 2023 | -39.7% |
| FY Dec 2022 | -23.0% |
| FY Dec 2021 | -19.0% |
| Jun 2026 | -2.7% |
| Mar 2026 | -38.5% |
| Dec 2025 | -16.5% |
| Sep 2025 | -12.8% |
| Jun 2025 | -14.1% |
| Mar 2025 | -10.9% |
| Dec 2024 | -26.2% |
| Sep 2024 | -43.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
31.04x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ARVN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 34.63x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$393.3M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ARVN
| FY Dec 2025 | $619.4M |
| FY Dec 2024 | $1.2B |
| FY Dec 2023 | $2.0B |
| FY Dec 2022 | $1.7B |
| FY Dec 2021 | $4.2B |
| Jun 2026 | $442.4M |
| Mar 2026 | $591.2M |
| Dec 2025 | $619.4M |
| Sep 2025 | $524.6M |
| Jun 2025 | $423.0M |
| Mar 2025 | $402.5M |
| Dec 2024 | $1.2B |
| Sep 2024 | $1.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-42.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield ARVN
| FY Dec 2025 | -36.2% |
| FY Dec 2024 | -19.8% |
| FY Dec 2023 | -15.5% |
| FY Dec 2022 | -15.4% |
| FY Dec 2021 | +12.8% |
| Jun 2026 | -38.9% |
| Mar 2026 | -37.9% |
| Dec 2025 | -36.2% |
| Sep 2025 | -52.7% |
| Jun 2025 | -74.3% |
| Mar 2025 | -52.4% |
| Dec 2024 | -19.8% |
| Sep 2024 | -15.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing ARVN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $262.6M | $263.4M | $78.5M | $131.4M |
| Operating income | -$118.5M | -$250.2M | -$401.5M | -$263.2M |
| Net income | -$81.0M | -$199.0M | -$367.0M | -$283.0M |
| EPS (diluted) | -1.14 | -2.77 | -6.62 | -5.31 |
| Operating cash flow | -$273.8M | -$259.3M | -$347.8M | -$273.5M |
| Cash | $142.9M | $100.5M | $311.7M | $81.3M |
| Long-term debt | $400.0K | $600.0K | $800.0K | $1.0M |
| Buybacks | $91.9M | $0 | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
ARVN Stock Sonar score 6/7 axes
Find similar shapesCompareARVN ranks highest on profitability (83rd percentile) and institutional and government (73rd), and lowest on insider conviction (21st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ARVN filings, in plain words
Are Arvinas insiders buying or selling ARVN?
In the 180 days to 2026-10-28, Arvinas insiders were net sellers, a net $518.2K across purchases and sales reported on Form 4, by 5 sellers.
Are there planned insider sales of ARVN?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $867.6K of stock; the latest, by SUNIL AGARWAL, was filed 2026-09-22.
Read the full summary
In the 180 days to 2026-10-28, Arvinas insiders were net sellers of ARVN, a net $518.2K across purchases and sales reported on Form 4 by 5 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $867.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
